[Comparative morpho-functional assessment of the impact produced by prolonged infusions of prostaglandins E and F on the course of genetically preconditioned arterial hypertension].
The administration of prolonged intravenous infusions of prostaglandins is defined; the method provided for specifying a long-term impact produced by prostaglandins on a nature of the course of genetically preconditioned arterial hypertension (AHT) in rats. Infusions of PGE-2 bring about a prolonged and stable reduction of mean arterial presser (AP) by 10% versus its original value; they intensify 2-fold the depressor baroreflectory regulation and stimulate the urinary excretion of endogenous renal PGF-2 alpha; besides, they contribute to a better blood supply to organs, i.e. an increased perfusion of the cortical and medullary layers of the kidneys and of the brain substances; and dilatation of the intramural branches of the coronary arteries, due to which the AP becomes milder. Infusions of PGF-2 alpha contribute to a prolonged and stable elevation of mean AP by 12% versus the original value; they inhibit the depressor baroreflectory regulation and intensify the pressor baroreflectory regulation; they, additionally, induce the urinary excretion of endogenous renal PGF-2 alpha and correct the lesions in the blood supply to organs, i.e. pathological microcirculation, anemia and spasm of the renal parenchyma, ischemic foci in the myocardium, spastic contraction of small cerebral arteries, edema and destructive changes (of the local necrosis variation) in the cerebral substance microvessels concomitant with a commencing diapedetic hemorrhages. Finally, all above listed lesions are signs of the malignant AP course.
A Iu
AIu
Runikhin
V I
VI
Savchuk
R I
RI
Sokolova
G G
GG
Arabidze
D000818:Animals; D001921:Brain / Q000473:pathology; D002536:Cerebral Arteries / Q000502:physiology; D003331:Coronary Vessels / Q000502:physiology; D006973:Hypertension / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology* / Q000652:urine; D006974:Hypertension, Malignant / Q000473:pathology / Q000503:physiopathology; D007262:Infusions, Intravenous; D007668:Kidney / Q000098:blood supply / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008833:Microcirculation; D011458:Prostaglandins E / Q000008:administration & dosage* / Q000502:physiology; D011460:Prostaglandins F / Q000008:administration & dosage* / Q000502:physiology / Q000652:urine; D051381:Rats; D011918:Rats, Inbred SHR; D013997:Time Factors
D011458:Prostaglandins E; D011460:Prostaglandins F